N&#45

3 trials

Sponsors

Faculty of Medicine, Thammasat University, Student Research Committee, The Faculty of Medicine Endowment fund

Conditions

Hepatocellular Carcinoma Hepatocellular Carcinoma Transarterial ChemoembolizationThalassemia major Thalassemia major HRV parameters Magnetic resonance acquisition N&#45hearing impairment Hearing Loss Intratympanic Injection Dexamethasone Acetylcysteine

Early Phase 1

Intratympanic Injections of N-acetylcysteine and Dexamethasone for Prevention of Cisplatin-induced Ototoxicity: Double Blind Randomized Clinical Trial

Active, not recruitingTCTR20160314003

Student Research Committeehearing impairment Hearing Loss Intratympanic Injection Dexamethasone Acetylcysteine

Start: 2013-02-01Updated: 2026-08-03

Phase 3

Intravenous N-acetyl-cysteine (NAC) for Prevention of Post-embolization Syndrome in Hepatocellular Carcinoma

RecruitingTCTR20150313002

Faculty of Medicine, Thammasat UniversityHepatocellular Carcinoma Hepatocellular Carcinoma Transarterial Chemoembolization

Start: 2015-02-01Target: 80Updated: 2026-08-03

Phase 4

Effects of N-acetylcysteine on cardiovascular parameters in thalassemia major patients

RecruitingTCTR20160725002

The Faculty of Medicine Endowment fundThalassemia major Thalassemia major HRV parameters Magnetic resonance acquisition N&#45

Start: 2015-12-01Updated: 2026-08-03

Related Papers

N-Acetylcysteine Prevents Post-embolization Syndrome in Patients with Hepatocellular Carcinoma Following Transarterial Chemoembolization.

2019-05-0910 citations